Comparative Pharmacology
Head-to-head clinical analysis: PEXEVA versus PROZAC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PEXEVA versus PROZAC.
PEXEVA vs PROZAC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Paroxetine is a selective serotonin reuptake inhibitor (SSRI); it potentiates serotonergic activity in the CNS by inhibiting the reuptake of serotonin at the presynaptic neuronal membrane.
Selective serotonin reuptake inhibitor (SSRI); potentiates serotonergic activity in the CNS by blocking the reuptake of serotonin into presynaptic neurons.
Initial 10 mg orally once daily, increased gradually based on response and tolerability; maximum 50 mg once daily (paroxetine hydrochloride equivalent).
20 mg orally once daily, initially; may increase to 40 mg once daily after several weeks; maximum 80 mg once daily.
None Documented
None Documented
60-120 hours (chronic dosing); steady-state achieved in 4-5 weeks
Fluoxetine: 4-6 days; norfluoxetine: 4-16 days; extensive accumulation with chronic dosing, steady-state in 4-5 weeks
Primarily renal (70% as metabolites, 2% unchanged); fecal (27%)
Renal: ~80% (primarily as metabolites, <10% unchanged); fecal: ~15%
Category C
Category C
SSRI Antidepressant
SSRI Antidepressant